$3.59
-0.11-2.97%
At close: -
$3.57
-0.02-0.56%
After Hours: 5:38 PM EDT
Comments
Loading...
Clover Health Investments Analyst Ratings and Price Targets | NASDAQ:CLOV | Benzinga
Clover Health Investments Corp has a consensus price target of $3.13 based on the ratings of 6 analysts. The high is $6 issued by Craig-Hallum on December 17, 2024. The low is $1.25 issued by Credit Suisse on March 6, 2023. The 3 most-recent analyst ratings were released by Canaccord Genuity, Craig-Hallum, and UBS on March 3, 2025, December 17, 2024, and October 7, 2024, respectively. With an average price target of $4.83 between Canaccord Genuity, Craig-Hallum, and UBS, there's an implied 35.39% upside for Clover Health Investments Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Craig-Hallum
UBS
Citigroup
Credit Suisse
1calculated from analyst ratings
Analyst Ratings for Clover Health Investments
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/03/2025 | Buy Now | 26.05% | Canaccord Genuity | Richard Close47% | $4.2 → $4.5 | Maintains | Buy | Get Alert |
| 12/17/2024 | Buy Now | 68.07% | Craig-Hallum | Matt Hewitt61% | → $6 | Initiates | → Buy | Get Alert |
| 10/07/2024 | Buy Now | 12.04% | UBS | Jonathan Yong64% | → $4 | Initiates | → Neutral | Get Alert |
| 08/11/2023 | Buy Now | -57.98% | Citigroup | Jason Cassorla50% | $1 → $1.5 | Maintains | Neutral | Get Alert |
| 03/06/2023 | Buy Now | -15.97% | Canaccord Genuity | Richard Close47% | $4 → $3 | Maintains | Buy | Get Alert |
| 03/06/2023 | Buy Now | -64.99% | Credit Suisse | Jonathan Yong64% | $2.5 → $1.25 | Maintains | Underperform | Get Alert |
| 11/16/2022 | Buy Now | -49.58% | Citigroup | Jason Cassorla50% | $3.5 → $1.8 | Maintains | Neutral | Get Alert |
| 11/08/2022 | Buy Now | -57.98% | SVB Leerink | Whit Mayo67% | $3 → $1.5 | Maintains | Market Perform | Get Alert |
| 08/09/2022 | Buy Now | -1.96% | Citigroup | Jason Cassorla50% | $3 → $3.5 | Maintains | Neutral | Get Alert |
| 08/09/2022 | Buy Now | -15.97% | Credit Suisse | Jonathan Yong64% | $3.5 → $3 | Maintains | Underperform | Get Alert |
| 05/10/2022 | Buy Now | -15.97% | SVB Leerink | Whit Mayo67% | $2.5 → $3 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Clover Health Investments (CLOV) stock?
The latest price target for Clover Health Investments (NASDAQ:CLOV) was reported by Canaccord Genuity on March 3, 2025. The analyst firm set a price target for $4.50 expecting CLOV to rise to within 12 months (a possible 26.05% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Clover Health Investments (CLOV)?
The latest analyst rating for Clover Health Investments (NASDAQ:CLOV) was provided by Canaccord Genuity, and Clover Health Investments maintained their buy rating.
When was the last upgrade for Clover Health Investments (CLOV)?
There is no last upgrade for Clover Health Investments
When was the last downgrade for Clover Health Investments (CLOV)?
There is no last downgrade for Clover Health Investments.
When is the next analyst rating going to be posted or updated for Clover Health Investments (CLOV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clover Health Investments, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clover Health Investments was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.
Is the Analyst Rating Clover Health Investments (CLOV) correct?
While ratings are subjective and will change, the latest Clover Health Investments (CLOV) rating was a maintained with a price target of $4.20 to $4.50. The current price Clover Health Investments (CLOV) is trading at is $3.57, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.